Evidence map›Paper›PMID 39376525›Full record

ArticleRSC advances2024

Mixed-ligand copper(ii)-diimine complexes of 3-formylchromone-

Anjaneyulu Mamindla, Dhanashree Murugan, Manikandan Varadhan, Tamilarasan Ajaykamal, Loganathan Rangasamy, Mallayan Palaniandavar, Venugopal Rajendiran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anjaneyulu MamindlaDepartment of Chemistry, School of Basic and Applied Sciences, Central University of Tamil Nadu Thiruvarur 610005 India rajendiran@cutn.ac.in.
Dhanashree MuruganDrug Discovery Unit (DDU), Centre for Biomaterials, Cellular and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT) Vellore 632014 Tamilnadu India.
Manikandan VaradhanDepartment of Chemistry, School of Basic and Applied Sciences, Central University of Tamil Nadu Thiruvarur 610005 India rajendiran@cutn.ac.in.
Tamilarasan AjaykamalSchool of Chemistry, Bharathidasan University Tiruchirappalli 620024 India.ORCID https://orcid.org/0000-0001-8914-5297
Loganathan RangasamyDrug Discovery Unit (DDU), Centre for Biomaterials, Cellular and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT) Vellore 632014 Tamilnadu India.
Mallayan PalaniandavarSchool of Chemistry, Bharathidasan University Tiruchirappalli 620024 India.ORCID https://orcid.org/0000-0003-4202-4572
Venugopal RajendiranDepartment of Chemistry, School of Basic and Applied Sciences, Central University of Tamil Nadu Thiruvarur 610005 India rajendiran@cutn.ac.in.ORCID https://orcid.org/0000-0003-2561-8387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The promising biological applications of thiosemicarbazone derivatives have inspired the design, synthesis, and study of their Cu(ii) complexes for anticancer therapeutic applications. Herein, we have evaluated the DNA/protein binding, DNA cleaving, and cytotoxic properties of four mixed-ligand Cu(ii) complexes of the type [Cu(L)(diimine)](NO

Identifiers

PMID39376525
PMCPMC11457010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.